Clinical and pathologic features of indolent and nonindolent disease in the whole cohort of patients with MCL
| Clinical and pathologic features . | Indolent disease, n = 17 (%) . | Nonindolent disease, n = 166 (%) . | P . |
|---|---|---|---|
| Median age, y (range) | 69.8 (41.1-87.1) | 69.5 (36.2-89.9) | |
| Male sex | 13/17 (76) | 116/166 (70) | NS |
| Age > 65 y | 11/17 (65) | 106/166 (64) | NS |
| B symptoms | 0/17 (0) | 71/163 (44) | < .001 |
| ECOG score ≥ 2 | 0/16 (0) | 7/159 (4) | NS |
| Nodal presentation (> 4 nodal sites) | 6/17 (35) | 107/163 (66) | .018 |
| Splenomegaly | 5/16 (31) | 80/150 (53) | NS |
| Ann Arbor Stage IV | 12/17 (71) | 141/166 (85) | NS |
| WBC count > 10 × 109/L | 5/17 (29) | 52/163 (32) | NS |
| Lymphocyte count > 5 × 109/L | 3/17 (18) | 45/160 (28) | NS |
| High serum LDH level | 3/16 (19) | 70/156 (45) | NS |
| MIPI high risk | 6/15 (40) | 61/126 (48) | NS |
| Ki-67 high (≥ 30%) | 2/14 (14) | 62/147 (42) | .048 |
| Ki-67 very high (≥ 50%) | 1/14 (7) | 29/147 (20) | NS |
| Blastoid structure (%) | 0/17 (0) | 21/146 (14) | NS |
| p53 positivity > 20% of cells by IHC | 2/17 (12) | 32/150 (21) | NS |
| CD23 positivity by flow cytometry | 12/17 (71) | 64/140 (46) | NS |
| SOX positivity | 15/17 (88) | 142/153 (93) | NS |
| Intense treatment without ASCT* | 0/17 (0) | 5/166 (3) | NS |
| ASCT | 1/17 (6) | 36/166 (22) | NS |
| Median overall survival (d)† | 2168 | 1031 | .004 |
| Clinical and pathologic features . | Indolent disease, n = 17 (%) . | Nonindolent disease, n = 166 (%) . | P . |
|---|---|---|---|
| Median age, y (range) | 69.8 (41.1-87.1) | 69.5 (36.2-89.9) | |
| Male sex | 13/17 (76) | 116/166 (70) | NS |
| Age > 65 y | 11/17 (65) | 106/166 (64) | NS |
| B symptoms | 0/17 (0) | 71/163 (44) | < .001 |
| ECOG score ≥ 2 | 0/16 (0) | 7/159 (4) | NS |
| Nodal presentation (> 4 nodal sites) | 6/17 (35) | 107/163 (66) | .018 |
| Splenomegaly | 5/16 (31) | 80/150 (53) | NS |
| Ann Arbor Stage IV | 12/17 (71) | 141/166 (85) | NS |
| WBC count > 10 × 109/L | 5/17 (29) | 52/163 (32) | NS |
| Lymphocyte count > 5 × 109/L | 3/17 (18) | 45/160 (28) | NS |
| High serum LDH level | 3/16 (19) | 70/156 (45) | NS |
| MIPI high risk | 6/15 (40) | 61/126 (48) | NS |
| Ki-67 high (≥ 30%) | 2/14 (14) | 62/147 (42) | .048 |
| Ki-67 very high (≥ 50%) | 1/14 (7) | 29/147 (20) | NS |
| Blastoid structure (%) | 0/17 (0) | 21/146 (14) | NS |
| p53 positivity > 20% of cells by IHC | 2/17 (12) | 32/150 (21) | NS |
| CD23 positivity by flow cytometry | 12/17 (71) | 64/140 (46) | NS |
| SOX positivity | 15/17 (88) | 142/153 (93) | NS |
| Intense treatment without ASCT* | 0/17 (0) | 5/166 (3) | NS |
| ASCT | 1/17 (6) | 36/166 (22) | NS |
| Median overall survival (d)† | 2168 | 1031 | .004 |
MCL indicates mantle cell lymphoma; ECOG, Eastern Cooperative Oncology Group; WBC, white blood cell; LDH, lactate dehydrogenase; MIPI, MCL International Prognostic Index; ASCT, autologous stem cell transplantation; and NS, not significant.
Two patients received high-dose cytosine arabinoside (AraC) or HyperCVAD (fractionated cyclophosphamide, vincristine, Adriamycin, and dexamethasone) with intention of ASCT but could not be transplanted, 1 patient got high-dose AraC as CNS prophylaxis, and 2 patients with kidney failure got high-dose AraC.
Excluding patients who received ASCT (indolent n = 1, nonindolent n = 36).